BBLG VS HSCS Stock Comparison

Performance

BBLG
10/100

BBLG returned -94.35% in the last 12 months. Based on SPY's performance of 9.73%, its performance is below average giving it a score of 10 of 100.

HSCS
10/100

HSCS returned -91.48% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Technicals

BBLG
14/100

BBLG receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

HSCS
11/100

HSCS receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

BBLG
49/100

BBLG has missed earnings 2 times in the last 20 quarters.

HSCS
100/100

HSCS has missed earnings 1 times in the last 20 quarters.

Profit

BBLG
10/100

Out of the last 20 quarters, BBLG has had 1 profitable quarters and has increased their profits year over year on 1 of them.

HSCS
10/100

Out of the last 10 quarters, HSCS has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

BBLG
46/100

BBLG has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.

HSCS
38/100

HSCS has had a lower than average amount of volatility over the last 12 months giving it a score of 38 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Bone Biologics Corp Common Stock Summary

Nasdaq / BBLG

Healthcare

Medical - Devices

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.

Heart Test Laboratories, Inc. Common Stock Summary

Nasdaq / HSCS

Healthcare

Medical - Devices

Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional 12-lead resting ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.

Power up your portfolio